AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00989469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib) and irinotecan (Campto)
Description: Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion
Study NCT01571557 — intervention group
Intervention type: DRUG
Intervention: dexamethasone 700 ug intravitreal implant
Description: dexamethasone 700 ug intravitreal implant administered according to standard of care.
Study NCT03310411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally
Study NCT03310411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Administered orally
Study NCT02285517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified Meek skin grafting technique
Description: patients with third degree of burns and without infected wounds are entered to the study and modified Meek skin grating technique is used to treat them and then the results of the procedure are compared to mesh skin grafting technique results by measuring the square centimeters of healed areas related to the technique
Study NCT03310411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: Administered orally
Study NCT03310411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Lasmiditan
Description: Administered orally
Study NCT03310411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Lasmiditan
Description: Administered orally
Study NCT02285517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mesh skin grafting technique
Description: patients with third degree of burns and without infected wounds are entered to the study and mesh skin grating technique is used to treat them and then the results of the procedure are compared to modified Meek skin grafting technique results by measuring the square centimeters of healed areas related to the technique
Study NCT03310411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Sumatriptan
Description: Administered orally
Study NCT03310411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Sumatriptan
Description: Administered orally
Study NCT03483376 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental prophylaxis
Description: Determining the effectiveness of dental prophylaxis alone in eliminating dental black stain.
Study NCT03483376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental prophylaxis
Description: Determining the effectiveness of dental prophylaxis alone in eliminating dental black stain.
Study NCT03483376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT)
Description: Establishing the effectiveness of dental prophylaxis combined with antimicrobial photodynamic therapy using blue light and curcumin as the photosensitizing agent in eliminating dental black stain.
Study NCT04059471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine, Institut Pasteur
Description: Full dose and 500IU/dose
Study NCT04059471 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccine, Institut Pasteur
Description: Full dose and 500IU/dose
Study NCT03954990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Oral
Description: 4 tablets (2 g of metronidazole)
Study NCT02796937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 MP
Description: Alpha-1 MP 60 mg/kg/week for up to 104 weeks
Study NCT04223531 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline 0.9% Infusion Solution Bag
Description: Participants will receive a normal saline infusion at a rate of 10ml per unit of body surface area per minute for 120 minutes.
Study NCT01520532 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI's will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at the Pre-Discharge will undergo an MRI at the 1 month follow-up visit.
Study NCT02302859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Participants receive an 8 week supply of Nicotine patches.
Study NCT02302859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at baseline on laptop, then weekly for 8 weeks on smartphone, then 3 months after smartphone intervention.
Study NCT02302859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pamphlet
Description: Pamphlet given to participant describing health and financial reasons to quit smoking.
Study NCT02302859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Counseling Sessions
Description: Standard Treatment (ST) Group: Participants receive 8 phone counseling sessions (one session per week) for support in quitting smoking. The calls should last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief video clips with advice on how to quit smoking over smartphone, as well as interactive text and picture messages once a week for 8 weeks. The video clips will be about 5 minutes long.~Participants also have access to additional counseling content on the smart phone, which can be used at any time.
Study NCT02302859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Test
Description: Participants complete saliva cotinine test 3 months after intervention.
Study NCT02302859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart phone
Description: Standard Treatment (ST) Group: Participants receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone.
Study NCT00548093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: PF-00299804 orally at 45 mg daily, on continuous schedule
Study NCT00986063 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic test for NVP induced rash
Description: The genotype statuses that capable of predict the cutaneous side effects from nevirapine
Study NCT00986063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3TC/D4T/NVP or 3TC/AZT/NVP
Description: Standard HAART for AIDS patients in Thailand
Study NCT01208220 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy
Description: NPWT changed 3 times weekly
Study NCT01208220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase Ointment
Description: Apply TIW
Study NCT02693093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-03
Study NCT02693093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03888950 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG PET-CT
Description: FDG PET/CT for oncological imaging of adult patients
Study NCT00813527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and fenofibrate
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT00813527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT03409393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The COPUS intervention
Description: The COPUS intervention consists of 8 weeks of High-Intensity Functional Training (HIFT). The frequency of the training is 3 sessions per week and the duration is one hour per session. The intervention is group-based and supervised. Each training session includes warm-up (15 min), followed by 30 minutes of HIFT based on a range of varied functional exercises, including elements of strength training and aerobic exercise. The sessions are supervised by a trained physiotherapist and exercise physiologist supported by 2 two trained bachelor students in Sports Science.
Study NCT03409393 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care (OPUS treatment)
Description: Usual care include specialised early intervention treatment (OPUS treatment) and consists of three main pillars: modified assertive treatment, family involvement, and social skill training. OPUS treatment is delivered via multidisciplinary teams include psychiatrists, psychologists, nurses, social workers, physiotherapists, and vocational therapists. All team members, except for the psychiatrist, function as case managers. The ratio of patients to case managers must not exceed 12:1.
Study NCT03409393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care (OPUS treatment)
Description: Usual care include specialised early intervention treatment (OPUS treatment) and consists of three main pillars: modified assertive treatment, family involvement, and social skill training. OPUS treatment is delivered via multidisciplinary teams include psychiatrists, psychologists, nurses, social workers, physiotherapists, and vocational therapists. All team members, except for the psychiatrist, function as case managers. The ratio of patients to case managers must not exceed 12:1.
Study NCT03853148 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Otago
Description: Exercise program for strength and balance
Study NCT03853148 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gentle yogic breathing
Description: yogic breathing
Study NCT03853148 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation
Description: Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities.
Study NCT03853148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Gentle yogic breathing
Description: yogic breathing
Study NCT04101500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Ipratropium Bromide Solution(C1) for Inhalation
Description: The patient's condition and basic condition were the same in the experimental group and the control group.
Study NCT04101500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Compound Ipratropium Bromide Solution(C1) for Inhalation
Description: The patient's condition and basic condition were the same in the experimental group and the control group.
Study NCT04101500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Sodium Chlolate and Aminophylline Tablets(C2)
Description: Applied only to the experimental group.
Study NCT04101500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Applied only to the control group.
Study NCT00119067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anthrax Vaccine Adsorbed
Study NCT00119067 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anthrax Vaccine Adsorbed
Study NCT00119067 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Study NCT02424643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary Incentive
Description: $20 Amazon.com gift card
Study NCT02424643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Altruistic Incentive
Description: A preliminary statement of the importance of participation, and periodic inspirational messages throughout the length of the survey emphasizing the value to men's health by completing the survey
Study NCT02424643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dashboard Incentive
Description: A sample dashboard will compare data subjects enter in their survey to the data already collected from other men who have taken the survey. For the dashboard, men who complete the survey will be shown how their own reported data about certain topics compared to other men's data.
Study NCT03080753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sphinkeeper
Description: Intersphincteric implants in the anal sphincter
Study NCT03866902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Physical Activity Intervention
Description: Mothers. Twelve weekly classes for one hour focused on nutrition and exercise education and coping skills training followed by a forty five minute exercise class for mothers. Then they will return for one hour for continued support and a forty-five minute exercise class.~Children. Twelve weekly classes for one hour focused on Color Me Healthy and one hour of free play. Then 6 monthly continued support classes where a Color Me Healthy class will be reviewed and they will have one hour of free play.
Study NCT03866902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: English for Second Language Intervention
Description: Mothers. Control group mothers will receive 12 weekly English for Second Language classes for one hour and forty-five minutes. Then 6 monthly one hour and forty minute follow-up classes receiving English for Second Language material.~Children. Control group children will receive 12 weekly one hour and forty five minutes of having books read to them. Followed by 6 monthly meetings for one hour and 45 minutes being read to and coloring with crayons.
Study NCT02861079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: An 18-F Foley catheter will insert into the endocervical canal and the balloon will fill with 30 mL of saline solution.
Study NCT02861079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGE2
Description: 10 mg PGE2 vaginal ovul (Propess,Ferring®) will place high into the posterior vaginal fornix.
Study NCT02861079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGE2
Description: 10 mg PGE2 vaginal ovul (Propess,Ferring®) will place high into the posterior vaginal fornix.
Study NCT03052959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Intervention
Description: The 'BETTER' prevention practitioner intervention involves assessment of a person's current participation, or lack of participation, among domains of evidence-based chronic disease prevention and surveillance (CDPS) actions. The assessment is followed several days later by a supportive meeting with a prevention practitioner nurse, using principles of shared decision making and health coaching, to establish goals for accomplishing CDPS activities of the individual's choice during the subsequent six months to develop personal goals and targets for participating in CDPS actions during the following six months. In BETTER HEALTH: DURHAM, the prevention practitioner nurse will be a public health nurse from the Durham Region Health Department.
Study NCT03052959 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait List Intervention
Description: The control arm will receive the prevention practitioner intervention 6 months after the intervention arm. Their outcomes will not be assessed in the study.
Study NCT02991677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise intervention
Description: Exercise physiologist supervised walking or running on the treadmill 3 times weekly for 12 weeks.
Study NCT02991677 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: weekly contact by study staff with survivorship information offered not related to neuropathy.
Study NCT02991677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistive training
Description: Exercise physiologist supervised upper and lower extremity resistive training 3 times weekly for 12 weeks
Study NCT01612299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zortress® /Everolimus
Description: Standard immunosuppression: THY 1-1.5 mg/kg/d qd for a total of 6 mg/kg •TAC trough targets 0-3 mo 8-12 ng/ml 4-6 mo 6-10 ng/ml >6 mo 5-8 ng/ml•Myfortic® or CEL 360mg or 500mg po BID, and receiving THY then Myfortic® or CEL 720 mg or 1000mg PO BID once THY induction completed• COR 500mg MET IV pre-op,125mg MET IV q24h x 2 doses (Post-Op Days 1 \&2) 20mg Pred PO daily x 2 wks 15mg Pred PO daily x 2 wks 10mg Pred PO daily x 4 wks 5mg Pred PO daily x 4 wks 5 mg Pred PO every other day through mon 12.~Experimental: TAC + Zortress® + COR In this arm patients will stop Myfortic®/CEL and start Zortress® at a dose of 1 mg PO BID with a target level of 3-8 ng/ml.At Zortress® level of at least 3 ng/ml TAC will be dosed to a target range as follows Randomization through mo 3 post-transplant 7-10 ng/ml 4-6 mo post transplant 5-8 ng/ml >6 mo post transplant 4-7 ng/ml.
Study NCT01612299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zortress® /Everolimus
Description: Standard immunosuppression: THY 1-1.5 mg/kg/d qd for a total of 6 mg/kg •TAC trough targets 0-3 mo 8-12 ng/ml 4-6 mo 6-10 ng/ml >6 mo 5-8 ng/ml•Myfortic® or CEL 360mg or 500mg po BID, and receiving THY then Myfortic® or CEL 720 mg or 1000mg PO BID once THY induction completed• COR 500mg MET IV pre-op,125mg MET IV q24h x 2 doses (Post-Op Days 1 \&2) 20mg Pred PO daily x 2 wks 15mg Pred PO daily x 2 wks 10mg Pred PO daily x 4 wks 5mg Pred PO daily x 4 wks 5 mg Pred PO every other day through mon 12.~Experimental: TAC + Zortress® + COR In this arm patients will stop Myfortic®/CEL and start Zortress® at a dose of 1 mg PO BID with a target level of 3-8 ng/ml.At Zortress® level of at least 3 ng/ml TAC will be dosed to a target range as follows Randomization through mo 3 post-transplant 7-10 ng/ml 4-6 mo post transplant 5-8 ng/ml >6 mo post transplant 4-7 ng/ml.
Study NCT03806712 — intervention group
Intervention type: OTHER
Intervention: multi method questionary (developped by De Rosa, in 1995 and 2014)
Description: questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)
Study NCT04622215 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ICIQ questionnaire
Description: questionnaire
Study NCT00807248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram placebo
Description: Once daily before bedtime for 8 weeks
Study NCT00807248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gaboxadol placebo
Description: Once daily before bedtime for 8 weeks
Study NCT00807248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gaboxadol placebo
Description: Once daily before bedtime for 8 weeks
Study NCT00807248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Description: Once daily before bedtime for 8 weeks
Study NCT00807248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram 20 mg
Description: Once daily before bedtime for 8 weeks
Study NCT00807248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gaboxadol 5 mg
Description: Once daily before bedtime for 8 weeks
Study NCT00807248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg
Description: Once daily before bedtime for 8 weeks
Study NCT03944174 — intervention group
Intervention type: PROCEDURE
Intervention: Fixation of unstable pelvic fractures
Description: Percutaneous fixation of both iliac bones through the sacrum using one screw
Study NCT03614897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education on guidelines for care of individuals at risk of falling
Study NCT01123837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fluid
Description: The treatment group will receive a 250cc bolus over 2 hrs of D5LR prior to the end of surgery and continued in the PACU. Blood glucose will be checked 3 different times using an Accu-chek monitor along with the type and number of rescue medications given at 30, 60, and 120 minutes after anesthesia and the post-op morning.~The control group will receive a 250cc bolus over 2 hours of LR. Blood glucose will be monitored 3 times along with the type and how much of rescue medications are given at 30, 60 and 120 minutes post-op and the morning after surgery.
Study NCT01123837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D5LR or lactated ringers
Description: The purpose of the study is to see if giving dextrose fluid in the veins (IV) decreases the risk of postoperative nausea and vomiting (PONV) in female urologic, gynecologic and breast outpatient surgery patients and at what blood sugar level.~The reason for this study is that IV dextrose may decrease the incidence of PONV and the use of medications to treat PONV, while leading to sooner discharge after surgery. This can decrease overall healthcare cost and improving patient satisfaction.
Study NCT01494935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Glycemic Diet
Description: NORMAL FAT AND GLYCEMIC DIET CONSUMED High FAT AND Glycemic Diet consumed
Study NCT00771160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Arm 1: montelukast tablet 5 mg, QD. Treatment period is 12-weeks. Arm 2: montelukast tablet 10 mg, QD. Treatment period is 12-weeks.
Study NCT01494935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control diet
Description: Normal fat, normal fat diet